Guliang XIA

罗氏免疫肿瘤负责人

• Dr Guliang Xia, currently the Head of Immunology Discovery at Roche R&D Center China in Shanghai. • Guliang received medical education from Tongji Medical University, PhD in Immunology from KU Leuven in Belgium, and post-doctor training at the Ohio State University and Medical College of Wisconsin. Then worked as Assistant Professor (Research) at Northwestern University in Chicago, as Principal Scientist and Manager in Immunology Drug Discovery, first at Astellas Pharma Inc (a site in Chicago), and then at Novo Nordisk Inc (a facility in Beijing). From 2015-2018, he worked at Synthetic Genomics Inc. in San Diego. • During his time in academia and industry, Guliang has published over 30 scientific papers, book chapters, one patent application, initiated and advanced multiple drug discovery projects. His research interest and expertise include immune target and drug discovery, immune regulation, cell /gene/genome therapy, transplant immunology, and autoimmune disease biology research.

荆志成

教授，中国医学科学院阜外医院，国家心血管病中心内科学和遗传学教授，主任医师

北京协和医学院首批“长聘教授” 教育部“长江学者特聘教授” 国家杰出青年科学基金获得者 国家“万人计划”科技创新领军人才 中华医学杂志（英文版）副总编辑 中华心血管病杂志 副总编辑 European Respiratory Review Associate Editor European Respiratory Journal 编委 北京医学会血栓与止血分会主任委员 科技北京“百名领军人才” 上海市领军人才 百千万人才工程国家级人选暨有突出贡献的中青年专家 科技部中青年科技创新领军人才 首届树兰医学青年奖获得者 国家科技部-比尔盖茨基金会-“大挑战.青年科学家奖”获得者 协和学者创新团队负责人

何洋

美国EXDA Consulting LLC.首席咨询顾问

毕业于纽约州立大学布法罗分校药学院，获得博士学位。在FDA担任新药资深审评专家，临床药理组长，曾审评过超过500个小分子和生物蛋白抗体类新药IND和NDA/BLA，参与编写和更新过多个FDA指南性文件，并独立主持多个FDA/CDER临床药理和定量药理学的研究课题。曾担任中国一家新药研发公司注册和临床药理副总裁。现任Univ of Iowa药学院的特聘客座教授。并在美国临床药理及治疗学会（ASCPT），担任抗感染疾病领域的指导委员会专家委员。

王在琪

InxMed首席执行官